This study analyzes US insurance claims data to understand the diagnostic journey of patients with hidradenitis suppurativa (HS). It reveals a significant delay in diagnosis, with patients often seeing non-dermatologists first, and highlights a shift in specialist care towards dermatology as the condition progresses.
What Problem Does This Paper Address?
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can cause significant pain, distress, and scarring. A major challenge for patients is the long wait time to receive a formal diagnosis, which can average nearly a decade. This delay likely contributes to disease progression and increased patient suffering. This paper aims to shed light on the patient's diagnostic pathway by analyzing real-world insurance claims data, specifically looking at which medical specialties are involved in the diagnosis and management of HS over time.
Methods
The researchers utilized the PatientSource data set, a comprehensive source of prescription, medical, and hospital claims. They analyzed a 2% random sample, representing approximately 5.9 million individuals, to identify patients with HS. HS patients were defined by specific International Classification of Diseases (ICD) codes (ICD-9 L73.2 or ICD-10 705.83) appearing at least once between July 2010 and January 31, 2022. To ensure a clear disease history, patients needed at least two years of prior claims data coverage. The study focused on the physician specialty recorded at the first, second, and third occurrences of an HS diagnosis code.
Datasets
The primary dataset used was the PatientSource data set (July 1, 2008 - January 31, 2022), provided by Symphony Health, an ICON plc Company. This dataset is an interconnected source of prescription, medical, and hospital claims across various payers, pharmacies, hospitals, and clinics. A 2% random sample of this database was analyzed, equating to approximately 5.9 million individuals. The study focused on a final cohort of 8,929 patients identified with HS.
Key Insights and Ideas
The "Diagnostic Odyssey" is Real: The data confirms the widely reported long wait times for an HS diagnosis, underscoring the significant challenges patients face in getting timely and accurate medical attention.
Primary Care as the First Point of Contact: Family medicine/general practice physicians are the most common specialists to first diagnose HS, indicating that initial patient encounters often occur outside of specialized dermatology settings.
Dermatology Becomes Central Over Time: While primary care physicians initiate the diagnostic process, dermatologists increasingly become the primary specialists managing HS as the condition progresses through second and third diagnosis occurrences.
Potential for Cost Savings: The decrease in emergency medicine specialists in the top 5 as HS progresses suggests a potential shift towards more consistent, specialized care, which could lead to reduced healthcare costs.
Key Results
The study analyzed a cohort of 8,929 HS patients.
The proportion of patients with HS in the dataset was 0.3%, aligning with existing literature.
The average age at first diagnosis was 37 years (SD: 15.5 years), with males diagnosed around 42 and females around 36.
First Diagnosis: Family medicine/general practice accounted for 24% of first diagnoses, followed by dermatology at 21%.
Second Diagnosis: Dermatology became the leading specialty (24%), with family medicine/general practice at 20%.
Third Diagnosis: Dermatology remained dominant (25%), with family medicine/general practice at 16%.
Emergency medicine's presence in the top 5 specialties decreased with subsequent HS diagnoses.
Limitations and Future Work
The authors acknowledge several limitations:
Potential for Missing Claims Data: The analysis relies on claims data, which might not capture every patient interaction or diagnosis, potentially affecting the accuracy of initial diagnosis dates.
Lack of Granular Disease Severity Data: The dataset does not provide detailed information on the severity of HS at the time of diagnosis, which could influence the choice of specialist.
Future research is suggested to:
Investigate the correlation between the severity of HS and the specialty of the physician providing the first diagnosis.
Focus on improving the diagnostic capabilities of non-dermatology specialists to expedite referrals and reduce patient wait times.
Summary updated
Abstract
To the Editor: Patients with hidradenitis suppurativa (HS) wait an average of almost 10 years to get a formal diagnosis, leading to significant pain, distress, and scarring.1Garg A. Neuren E. Cha D. et al.Evaluating patients' unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) project.J Am Acad Dermatol. 2020; 82: 366-376https://doi.org/10.1016/j.jaad.2019.06.1301Abstract Full Text Full Text PDF PubMed Scopus (158) Google Scholar,2Jfri A. Nassim D. O'Brien E. Gulliver W. Nikolakis G. Zouboulis C.C. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis.JAMA Dermatol. 2021; 157: 924-931https://doi.org/10.1001/jamadermatol.2021.1677Crossref PubMed Scopus (76) Google Scholar To better understand the patient journey from the initial diagnosis of HS, we utilized the PatientSource data set (July 1, 2008-January 31, 2022) from Symphony Health, an ICON plc Company. This is an interconnected source of prescription, medical, and hospital claims across payers, pharmacies, hospitals, and clinics. A 2% random sample from the PatientSource database, equating to 5.9 million individuals, was analyzed to identify patients with HS. We define HS patients as having 1 or more claims of HS diagnoses3Strunk A. Midura M. Papagermanos V. Alloo A. Garg A. Validation of a case-finding algorithm for hidradenitis suppurativa using administrative coding from a clinical database.Dermatology. 2017; 233: 53-57https://doi.org/10.1159/f000468148Crossref PubMed Scopus (0) Google Scholar using the International Classification of Diseases, Ninth Revision code L73.2 or 1 or more instance(s) of the 10th Revision code 705.83 between July 2010 and January 31, 2022. The index date is the date of the first identified diagnosis of HS. To capture disease history, it is required that patients have at least 2 years of claims data coverage prior to the index date, which is defined as at least 1 claim of any type (prescription, medical, or hospital) in each of the 2 years prior to the index date. The analysis was performed on a final cohort of 8929 patients, with all 50 US states represented. The proportion of patients with HS in the data set was 0.3%, in line with statistics identified from published literature.2Jfri A. Nassim D. O'Brien E. Gulliver W. Nikolakis G. Zouboulis C.C. Prevalence of hidradenitis suppurativa: a systematic review and meta-regression analysis.JAMA Dermatol. 2021; 157: 924-931https://doi.org/10.1001/jamadermatol.2021.1677Crossref PubMed Scopus (76) Google Scholar To understand the patient journey, we assessed the physician specialty seen at first diagnosis, and second and third occurrence of HS diagnosis codes. Approximately 75% of the HS diagnoses in the data set have a physician specialty recorded. The average age at first diagnosis is 37 years (SD: 15.5 years), with male and female patients diagnosed at an average age of 42 and 36, respectively. Family medicine/general practice specialties make the highest percentage of first diagnosis (24%) followed by dermatology (21%). Other groups involved in making the first diagnosis include internal medicine, general surgery, and emergency medicine (Fig 1). However, after the first diagnosis, dermatologists become the leading specialist seen at the second occurrence (24% dermatology and 20% family medicine/general practice) and at the third occurrence (25% dermatology and 16% family medicine/general practice). After initial diagnosis and subsequent increase in care by dermatologists, the presence of emergency medicine in the top 5 specialties decreases (Fig 1), which could result in lower medical costs. Given the results from this study, it is likely that patients have been seen many times by nondermatology specialists prior to diagnosis, therefore efforts should focus on improving diagnostic ability of these groups to increase rates and speed of referral to dermatologists. Limitations of this study include potentially missing claims data (for determining initial diagnosis), and lack of granular data on disease severity at diagnosis. Future research should look at the correlation between severity of disease and specialty at first diagnosis. Authors Ali and Williams are employees of UCB Pharma. Author Xiong, Dr Zou, and Dr Daneshjou have no conflicts of interest to declare.
BibTeX
@inproceedings{xiong2023diagnosis,
author = {Betty Xiong and James Zou and Waqar Ali and Roxana Daneshjou and Jonathan Williams},
title = {{Diagnosis and management of hidradenitis suppurativa: Analysis of US insurance claims data}},
booktitle = {JAAD},
year = {2023},
doi = {10.1016/j.jdin.2023.10.002},
}